News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Liberty Global shares trade near $8 after a recent collapse in sentiment.
  • Liberty Global reported EPS of -$8.90 and free cash flow of -$254.8M.
  • Valuation sits around 0.30x book, EV about $8.67B, and EV/EBITDA roughly 7.6x.
  • Trade plan: buy Liberty at $8.00, stop $6.50, target $12.00 over 180 trading days.
  • Microsoft trades near $535 with a P/E of about 30.
  • Microsoft faces a potential $25B incremental AI-related cost base.
  • If Microsoft cuts that cost by about 60%, the stock could reach roughly $856, implying ~60% upside over 180 trading days.

Latest Articles

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

Keros Therapeutics, a clinical-stage biopharmaceutical company, announced dosing of the first patient in its Phase 2 trial evaluating rinvatercept in patients with Duchenne muscular dystrophy (DMD). The trial aims to assess safety, tolerability, and functional improvements in late-ambulatory and early non-ambulatory DMD patients, signaling progress…

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Lantheus Holdings has initiated dosing in the SPARROW Phase 2/3 registrational trial for LNTH-2401, a gallium-68-labelled PET imaging agent targeting the GRPR biomarker in prostate cancer. This trial aims to assess the sensitivity and specificity of LNTH-2401 PET/CT imaging compared to histopathology in approximately 400 patients, potentially expan…

Winnebago Industries Names Simone Silva Vice President to Lead Enterprise Aftermarket and Customer Experience Strategy

Winnebago Industries Names Simone Silva Vice President to Lead Enterprise Aftermarket and Customer Experience Strategy

Winnebago Industries has appointed Simone Silva as Vice President of Aftermarket and Enterprise Customer Experience, a newly created role aimed at expanding the company's aftermarket business and strengthening customer engagement across its premium outdoor recreation brands. Silva brings over 20 years of customer service leadership, with previous r…

Maris-Tech Receives Record US$10 Million Order - Its Largest-Ever Contract - for Advanced Video Systems on Next-Generation Airborne Defense Platforms

Maris-Tech Receives Record US$10 Million Order - Its Largest-Ever Contract - for Advanced Video Systems on Next-Generation Airborne Defense Platforms

Maris-Tech Ltd., a Nasdaq-listed company specializing in AI-powered edge video solutions for defense, received its largest-ever $10 million order to supply advanced video systems for multiple next-generation manned airborne platforms. The order, part of a multi-year project with Magam Safety Ltd., has potential additional purchase options that coul…

NaaS Technology Inc.'s Parent Company Named to 2026 China Top 500 Private Enterprises List, Recognized for AI-Driven Energy Digitalization

NaaS Technology Inc.'s Parent Company Named to 2026 China Top 500 Private Enterprises List, Recognized for AI-Driven Energy Digitalization

Shandong Energy Chain Holding Co., Ltd., a subsidiary of Newlinks Technology Limited and parent company of NaaS Technology Inc. (Nasdaq: NAAS), was ranked No. 401 on the 2026 China Top 500 Private Enterprises list. This recognition highlights Newlinks' leadership in advancing energy digitalization and AI integration in China's energy sector. NaaS, …

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

SCYNEXIS, Inc. announced a significant contract award from the U.S. government's BARDA, potentially providing up to $214 million in non-dilutive funding to advance SCY-247, its second-generation antifungal drug candidate, through critical development stages including Phase 2 trials and NDA submission. This funding strengthens the company’s pipeline…

Fusemachines Accelerates AI Twin Development Through Access to IBM Fusion Infrastructure Provided by IBM Platinum Partner modulAIre

Fusemachines Accelerates AI Twin Development Through Access to IBM Fusion Infrastructure Provided by IBM Platinum Partner modulAIre

Fusemachines Inc. announced enhanced access to modulAIre's IBM Fusion AI-optimized infrastructure at a nominal cost, accelerating the development of its AI Twin technology. This expanded infrastructure enables faster experimentation and refinement of complex AI models, supporting Fusemachines' goal to advance intelligent digital representations for…

Valley National Bancorp to Acquire Bluevine Inc., Accelerating Its Digital Small Business Growth Strategy and Meaningfully Enhancing Its Core Funding Capabilities

Valley National Bancorp to Acquire Bluevine Inc., Accelerating Its Digital Small Business Growth Strategy and Meaningfully Enhancing Its Core Funding Capabilities

Valley National Bancorp announced an agreement to acquire Bluevine Inc., a leading digital banking platform for small businesses. The acquisition aligns with Valley's strategy to enhance its core funding, expand its small business franchise, and accelerate its digital and AI capabilities. Bluevine brings $2.1 billion in low-cost digital deposits, a…

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer

Immuneering Corporation presented compelling Phase 2a clinical data at the 2026 AACR Conference demonstrating that their drug atebimetinib, combined with chemotherapy, may extend survival in pancreatic cancer patients by reducing tumor volume and preserving body mass. Patients maintaining or gaining weight had significantly longer overall survival,…

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Palvella Therapeutics announced it received a third year of FDA grant funding to support Phase 3 trials of QTORIN™ rapamycin for microcystic lymphatic malformations, a rare disease affecting over 30,000 patients. Following positive Phase 3 SELVA trial results, the company completed its New Drug Application submission and is preparing for a potentia…

Quantum Cyber Files Audited and Reviewed Financial Statements and Pro Forma Financial Information for Bridgeport Manufacturing Acquisition

Quantum Cyber Files Audited and Reviewed Financial Statements and Pro Forma Financial Information for Bridgeport Manufacturing Acquisition

Quantum Cyber N.V. (Nasdaq: QUCY) has filed audited historical financial statements and pro forma financial information related to its acquisition of Bridgeport, Connecticut manufacturing facility and operating business of Arcade Technology LLC and Arcade Realty LLC. The acquisition was completed entirely with cash and no debt was assumed. The acqu…

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

CervoMed announces a new 50 mg oral tablet formulation of neflamapimod with improved pharmacokinetics suitable for twice-daily dosing, following FDA removal of a previous plasma drug exposure limit. The company plans to advance a 100 mg twice-daily regimen expected to yield higher trough plasma concentrations linked to clinical activity. Manufactur…

B2Gold Provides Operations Update for the Goose Mine and Announces Drill Results at the Back River Gold District

B2Gold Provides Operations Update for the Goose Mine and Announces Drill Results at the Back River Gold District

B2Gold Corp. has provided an operational update on its Goose Mine highlighting the commissioning of a new mobile crushing plant achieving targeted throughput following fire damage earlier in 2026. The company is on track to meet its annual gold production guidance of 170,000 to 200,000 ounces. Additionally, positive results from the 2026 exploratio…

Armlogi Holding Corp. Reports Fiscal Year 2026 Financial Results; Warehousing Services Revenue Grows 21.9% to $77.1 Million

Armlogi Holding Corp. Reports Fiscal Year 2026 Financial Results; Warehousing Services Revenue Grows 21.9% to $77.1 Million

Armlogi Holding Corp. reported fiscal 2026 revenues of $185.8 million with warehousing services up 21.9% to $77.1 million, making up 41.5% of total revenue. Transportation services revenue declined 14.5%. Gross profit turned positive at $0.4 million compared to a loss last year, but net loss widened to $20.9 million. The company fully settled conve…